Klein B, Sadikov E, Mishaeli M, Levin I, Figer A
Oncology Unit, Rabin Medical Center, Golda Campus, Petach-Tikva 49372, Israel.
Oncol Rep. 2000 Jul-Aug;7(4):875-7. doi: 10.3892/or.7.4.875.
Gemcitabine has been recently added to the 5-fluorouracil (5-FU) protocol in the treatment of both new and 5-FU refractory patients with pancreatic cancer. We compared the efficacy of gemcitabine versus 5-FU and leucovorin (LCV) in 82 patients with advanced pancreatic cancer. Forty-seven patients received 5-FU and LCV and 35 patients received gemcitabine. Objective responses were documented in 4% on the 5-FU and LCV arm, compared to 9% in the gemcitabine arm. No change was observed in 48% on the 5-FU and LCV arm compared to 20% in the gemcitabine arm. Clinical benefit was observed in 19% on the 5-FU and LCV arm compared to 48% in the gemcitabine arm (p<0. 001). Toxicity was mild and well tolerated in both arms. One-year survival was 32% on the 5-FU and LCV arm and 23% in the gemcitabine arm. These results indicate that gemcitabine had a significantly higher clinical benefit than 5-FU and should be the standard treatment in advanced pancreatic cancer.
吉西他滨最近已被添加到5-氟尿嘧啶（5-FU）方案中，用于治疗新诊断的以及对5-FU耐药的胰腺癌患者。我们比较了吉西他滨与5-FU和亚叶酸（LCV）对82例晚期胰腺癌患者的疗效。47例患者接受5-FU和LCV治疗，35例患者接受吉西他滨治疗。5-FU和LCV治疗组的客观缓解率为4%，而吉西他滨治疗组为9%。5-FU和LCV治疗组48%的患者病情无变化，而吉西他滨治疗组为20%。5-FU和LCV治疗组19%的患者观察到临床获益，而吉西他滨治疗组为48%（p<0.001）。两组的毒性均较轻且耐受性良好。5-FU和LCV治疗组的一年生存率为32%，吉西他滨治疗组为23%。这些结果表明，吉西他滨的临床获益显著高于5-FU，应成为晚期胰腺癌的标准治疗方法。
